vimarsana.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report sent to investors on Monday. The firm issued a sell rating on the stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $2.50 target price on shares of VolitionRx in a research report on Thursday, May 16th. Get […]

Related Keywords

United States , ,Exchange Commission ,Volitionrx Limited ,Silverberg Bernstein Capital Management ,Volitionrx Company Profile ,Cantor Fitzgerald ,Free Report ,Get Free Report ,Bernstein Capital Management ,Volitionrx Daily ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.